Education
About Us
Working with TipRanks
Follow Us
Glaukos Corp. (GKOS)
:GKOS
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$77.91 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.09M
Market Cap
$4.73B
Enterprise Value$8.12B
Total Cash (Recent Filing)$6.73M
Total Debt (Recent Filing)$17.50M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Apr 30, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding56,567,387
10 Day Avg. Volume930,444
30 Day Avg. Volume1,089,649
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.08
Price to Cash Flow (P/CF)2754.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.06
Enterprise Value/Ebitda-90.36
Forecast
1Y Price Target
$164.50Price Target Upside96.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Glaukos News
PremiumCompany Announcements
Glaukos Highlights Strategic Focus in 2024 Presentation
PremiumCompany Announcements
Glaukos Corp. Reports Record Sales in Earnings Call
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's iDose sales in the US significantly contributed to a strong financial performance, offsetting recent reimbursement challenges in other areas.
IDose OpportunityGlaukos Corp is more optimistic about the iDose opportunity due to positive clinical outcomes, improved surgeon training, and reimbursement progress.
Revenue GrowthIDose sales nearly doubled in 4Q to ~$15.5M and are expected to reach $100M+ in FY25, indicating strong growth potential for this product.
Bears Say
Local Coverage DeterminationsRecent changes in Local Coverage Determinations (LCD) for core MIGS are expected to negatively impact business performance until existing challenges are overcome.
Stock Price DeclineShares of Glaukos Corp. experienced a decline due to concerns about the 2025 US iDose outlook, particularly related to local coverage determinations affecting the core US MIGS franchise.
US MIGS SalesUS MIGS sales were negatively impacted by local coverage determinations, leading to a slower growth rate.
---
Ownership Overview
5.91% Insiders
41.96% Mutual Funds
0.19% Other Institutional Investors
26.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos Corp.’s price range in the past 12 months?
Glaukos Corp. lowest stock price was $77.91 and its highest was $163.71 in the past 12 months.
What is Glaukos Corp.’s market cap?
Glaukos Corp.’s market cap is $4.73B.
When is Glaukos Corp.’s upcoming earnings report date?
Glaukos Corp.’s upcoming earnings report date is Apr 30, 2025 which is in 23 days.
How were Glaukos Corp.’s earnings last quarter?
Glaukos Corp. released its earnings results on Feb 20, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.383 by -$0.017.
Is Glaukos Corp. overvalued?
According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued.
Does Glaukos Corp. pay dividends?
Glaukos Corp. does not currently pay dividends.
What is Glaukos Corp.’s EPS estimate?
Glaukos Corp.’s EPS estimate is -0.35.
How many shares outstanding does Glaukos Corp. have?
Glaukos Corp. has 56,567,387 shares outstanding.
What happened to Glaukos Corp.’s price movement after its last earnings report?
Glaukos Corp. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.383. Following the earnings report the stock price went down -20.005%.
Which hedge fund is a major shareholder of Glaukos Corp.?
Currently, no hedge funds are holding shares in GKOS
---
Glaukos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$164.50 (96.65% Upside)
$164.50 (96.65% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 22.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.9%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
-23.83%
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Glaukos Corp.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
---
GKOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record sales growth, driven by the U.S. and international glaucoma franchises, and positive clinical developments. However, challenges such as LCD impacts, foreign exchange headwinds, and Medicaid rebate effects on corneal health were noted. The company remains optimistic about its strategic plans and financial position.Read More>---
GKOS Stock 12 Month Forecast
Average Price Target
$164.50
▲(96.65% Upside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
Inspire Medical Systems
―
PROCEPT BioRobotics
―
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+16.35%
upgraded a buy rating 4 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.35% per trade.
---